CaltechAUTHORS
  A Caltech Library Service

Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin

Davis, Mark E. (2009) Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin. Advanced Drug Delivery Reviews, 61 (13). pp. 1189-1192. ISSN 0169-409X. doi:10.1016/j.addr.2009.05.005. https://resolver.caltech.edu/CaltechAUTHORS:20091211-112153607

Full text is not posted in this repository. Consult Related URLs below.

Use this Persistent URL to link to this item: https://resolver.caltech.edu/CaltechAUTHORS:20091211-112153607

Abstract

IT-101 (Insert Therapeutics-101) is a linear, cyclodextrin-containing polymer conjugate of camptothecin (CPT). When formulated properly, the polymer conjugate self-assembles into nanoparticles of ca. 30 nm diameter and near neutral zeta potential. The nanoparticles show long circulation half-lives in animals and humans and localize in tumors. The nanoparticles enter the tumor cells and slowly release the CPT causing them to disassemble into individual polymer chains that are sufficiently small to be cleared renally. IT-101 is currently being investigated in human clinical trials. Here, the design and development of IT-101 is described with emphasis on features distinguishing it from other polymer-containing therapeutics.


Item Type:Article
Related URLs:
URLURL TypeDescription
http://dx.doi.org/10.1016/j.addr.2009.05.005DOIArticle
ORCID:
AuthorORCID
Davis, Mark E.0000-0001-8294-1477
Additional Information:© 2009 Elsevier B. V. Received 7 May 2009; accepted 13 May 2009. Available online 12 August 2009. I thank all my co-investigators who are listed on the publications referenced. I especially thank Thomas Schluep, who is the Chief Science Officer of Insert Therapeutics (now merged with Calando Pharmaceuticals, Inc.) for leading the efforts of taking laboratory scale materials into the clinic. Finally, I thank Jamie Oliver for his leadership in the clinical programs with IT-101. Lastly, I thank the patients who willingly participated in the clinical trials.
Subject Keywords:IT-101; Cyclodextrin polymer; Camptothecin; Clinical trials
Issue or Number:13
DOI:10.1016/j.addr.2009.05.005
Record Number:CaltechAUTHORS:20091211-112153607
Persistent URL:https://resolver.caltech.edu/CaltechAUTHORS:20091211-112153607
Official Citation:Mark E. Davis, Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin, Advanced Drug Delivery Reviews, Volume 61, Issue 13, Polymer Therapeutics: Clinical Applications and Challenges for Development, 12 November 2009, Pages 1189-1192, ISSN 0169-409X, DOI: 10.1016/j.addr.2009.05.005. (http://www.sciencedirect.com/science/article/B6T3R-4X08779-1/2/2525beba4db1b1312757e89655730a34)
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:16961
Collection:CaltechAUTHORS
Deposited By: Tony Diaz
Deposited On:04 Jan 2010 19:45
Last Modified:08 Nov 2021 23:31

Repository Staff Only: item control page